GRI Bio to present Phase 2a GRI-0621 data at ERS 2026
GRI Bio says it will present late-breaking Phase 2a GRI-0621 data on lung function, anti-fibrotic biomarkers and tolerability in IPF at ERS 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.